These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23630214)

  • 21. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
    Ku GY; Haaland BA; de Lima Lopes G
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):231-8. PubMed ID: 22699811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status.
    Modest DP; Stintzing S; Laubender RP; Neumann J; Jung A; Giessen C; Haas M; Aubele P; Schulz C; Boeck S; Stemmler HJ; Kirchner T; Heinemann V
    Anticancer Drugs; 2011 Oct; 22(9):913-8. PubMed ID: 21795973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cetuximab or Bevacizumab With First-Line Chemotherapy in Advanced KRAS Wild-Type Colorectal Cancer: No Difference, but Not the Same.
    Lieu CH; Messersmith WA
    JAMA; 2017 Jun; 317(23):2376-2378. PubMed ID: 28632850
    [No Abstract]   [Full Text] [Related]  

  • 24. Chemotherapy and immunotherapy in metastatic colorectal cancer.
    Pohlmann PR; Mernaugh RL; Goff LW
    N Engl J Med; 2009 May; 360(20):2134; author reply 2135-6. PubMed ID: 19439750
    [No Abstract]   [Full Text] [Related]  

  • 25. Should the results of the new EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver?
    Nordlinger B; Poston GJ; Goldberg RM
    J Clin Oncol; 2015 Jan; 33(3):241-3. PubMed ID: 25403221
    [No Abstract]   [Full Text] [Related]  

  • 26. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab.
    Piessevaux H; Buyse M; Schlichting M; Van Cutsem E; Bokemeyer C; Heeger S; Tejpar S
    J Clin Oncol; 2013 Oct; 31(30):3764-75. PubMed ID: 24043732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biomarkers and efficacy: are we nearly there yet?
    Russo A; Rizzo S
    Ann Oncol; 2011 Jul; 22(7):1469-1470. PubMed ID: 21551003
    [No Abstract]   [Full Text] [Related]  

  • 29. Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?
    Garassino MC; Farina G; Rossi A; Martelli O; Torri V
    J Clin Oncol; 2008 May; 26(15):2600; author reply 2601-2. PubMed ID: 18487581
    [No Abstract]   [Full Text] [Related]  

  • 30. Impact of early tumor shrinkage on clinical outcome in wild-type-KRAS colorectal liver metastases treated with cetuximab.
    Ye LC; Wei Y; Zhu DX; Chen T; Xu J
    J Gastroenterol Hepatol; 2015 Apr; 30(4):674-9. PubMed ID: 25387601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
    Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
    Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
    Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
    Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
    Van Cutsem E; Lenz HJ; Köhne CH; Heinemann V; Tejpar S; Melezínek I; Beier F; Stroh C; Rougier P; van Krieken JH; Ciardiello F
    J Clin Oncol; 2015 Mar; 33(7):692-700. PubMed ID: 25605843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.
    Modest DP; Brodowicz T; Stintzing S; Jung A; Neumann J; Laubender RP; Ocvirk J; Kurteva G; Papai Z; Knittelfelder R; Kirchner T; Heinemann V; Zielinski CC
    Oncology; 2012; 83(5):241-7. PubMed ID: 22948721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer.
    Shitara K; Ura T; Matsuo K; Takahari D; Yokota T; Yuki S; Yoshida M; Utsunomiya S; Sato Y; Yamaura H; Kato M; Inaba Y; Tajika M; Kawai H; Yamazaki K; Komatsu Y; Muro K
    Eur J Cancer; 2011 Dec; 47(18):2673-80. PubMed ID: 21652203
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.
    Sohn BS; Kim TW; Lee JL; Ryu MH; Chang HM; Kang YK; Park HS; Na YS; Jang SJ; Kim JC; Lee JS
    Oncology; 2009; 77(3-4):224-30. PubMed ID: 19738388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
    Tejpar S; Celik I; Schlichting M; Sartorius U; Bokemeyer C; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3570-7. PubMed ID: 22734028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.
    Scartozzi M; Mandolesi A; Giampieri R; Pierantoni C; Loupakis F; Zaniboni A; Galizia E; Giustini L; Silva RR; Bisonni R; Berardi R; Biagetti S; Menzo S; Falcone A; Bearzi I; Cascinu S
    Int J Cancer; 2010 Oct; 127(8):1941-7. PubMed ID: 20099280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Managing advanced colorectal cancer: have we reached the PEAK with current therapies?
    Wolpin BM; Bass AJ
    J Clin Oncol; 2014 Jul; 32(21):2200-2. PubMed ID: 24934780
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.